Announcements
- Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
- Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
- Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.76 |
---|---|
High | 10.40 |
Low | 9.76 |
Bid | 10.02 |
Offer | 10.44 |
Previous close | 10.36 |
Average volume | -- |
---|---|
Shares outstanding | 67.66m |
Free float | 33.99m |
P/E (TTM) | -- |
Market cap | 4.18m CHF |
EPS (TTM) | -0.2547 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼